PSYCHOPHARMOCOTHERAPY FOR PHOBIC AND OBSESSIVE-COMPULSIVE DISORDERS IN SCHIZOPHRENIA SPECTRUM STATES
https://doi.org/10.14412/2074-2711-2009-56
Abstract
The paper describes the results of psychopharmacotherapy for obsessive-phobic disorders (OPD) in the structure of schizophrenia spectrum states. It is shown that not only the clinicodynamic features of OPD, but also the course of a schizophrenic process and the pattern of comorbid mental disorders should be borne in mind when therapy is chosen. The OPD variants that are associated with the best and worst prognosis in terms of medical therapy are identified.
About the Authors
A. V. Pavlichenko
Russian State Medical University;
N.A. Alekseyev City Clinical Mental Hospital One
Russian Federation
Moscow
Russian Federation
Moscow
L. G. Kessel'man
Russian State Medical University;
N.A. Alekseyev City Clinical Mental Hospital One
Russian Federation
Moscow
Russian Federation
Moscow
References
1. <div><p>Koran L., Saltee F., Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;154:396-401.</p><p>Мосолов С.Н. Клиническое применение антидепрессантов. СПб., 1995;566 с.</p><p>Tamimi R., Mavissakalian M.R., Jones B. et al. Clomipramine versus Fluvoxamine in obsessive-compulsive disorder. Ann Clin Psychiatry 1991;3:275-9.</p><p>Jenike M.A., Baer L., Minichiello W.E. et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261-4.</p><p>Montgomery S.A., Kasper S., Stein D.J. et al. Citalopram 20 mg, 40 mg and 60 mg are all effec- tive and well toletated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;6(1):75-86.</p><p>Bisserbe J., Lane R.M., Flament M. et al. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disord. Eur Psychitry 1997;12:82-93.</p><p>Hollander E., Simeon D. Concise guide to anxiety disorder. APP, Washington, London, 2003; 252 p.</p><p>Montgomery S., Zohar J. Obsessive-compulsive Disorder. London: Martin Dunitz, 1999.</p><p>Zohar J., Maj M., Sartorius N., Okasha O., eds. Obsessive-compulsive Disorder. London: John Wiley & Sons, 2000.</p><p>Geller D.A., Biederman J., Stewart S.E. et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003;160:1919-28.</p><p>Hollander E., Evers M. Review of obsessive-compulsive spectrum disorders: what do we know? Clinical neuropsychiatry 2004;1:32-51.</p><p>McDougle C.J., Goodman W.K., Leckman J.F. et al. Haloperidol addition in fluvoxamine-refractory treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled study in patient with and without tics. Arch Gen Psychiatry 1994;51:302-8.</p><p>Колюцкая Е.В. Обсессивно-фобические расстройства в рамках шизофрении и расстройств шизофренического спектра. Автореф. дис. ... д-ра мед. наук. М., 2001.</p><p>Ravizza L., Barzega G., Bellino S. et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder. Psychopharmacol Bull 1996;32:677-82.</p><p>Stein D., Bouwer G., Hawkridge S., Emsley R.A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. Clin Psychiatry 1997;58:119-22.</p><p>Eriksson E. Brain neurotransmission in panic disorder. Acta Psychiatr Scand 1987; 335(Suppl.):31-37.</p><p>Калинин В.В. Современная фармакотера- пия тревожных состояний. Новые достиже- ния в терапии психических заболеваний. М., 2002;409-31.</p><p>Bowen R., South M., Fischer D., Looman T. Depression, mastery and number of group sessions attended predict outcome of patients with panic and agoraphobia in a behavioral/medication program. Can J Psychiatry 1994;39(5):283-8.</p><p>Ito L.M., Gorenstein C., Gentil V., Miyakawa E. Minnesota Multiphase Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment. Braz J Med Biol Res 1995;28:961-5.</p><p>Woods S., Black D. Fluvoxamin in the treatment of panic disorder in outpatients. Neuropsychopharmacology 1994;10:103.</p><p>Charney D., Breier A. Agoraphobia with panic attacks. Development, diagnostic stability, and course of illness. Arch Gen Psychiatry 1986;43:1029-36.</p><p>Сергеев И.И. Место антидепрессантов в терапии фобий. Психиатр. и психофармакотер. Прил. 3 2001; с. 8-11.</p><p>Cowley D., Roy-Byrne P. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 1995;12:147-57.</p><p>Sutherland S., Tupler L. A 2-year follow-up of social phobia. Status after a brief medication trial. J Nerv Ment Dis 1996;184:731-8.</p><p>Иванов С.В., Ильина Н.А., Бурлаков А.В. Спектр терапевтической эффективности и безопасность применения лорафена при тревожных расстройствах. Журн. невропатол. и психиатр. 2003;(8):38-41.</p><p>Смулевич А.Б., Колюцкая Е.В., Иванов С.В. Обсессивно-фобические расстройства с паническими атаками и явлениями стойкой агорафобии (клиника, прогноз, терапия). Соц. и клин. психиатр. 1998;(4):40-8.</p><p>Лакосина Н.Д., Колупаев Г.П. Дифференциальная диагностика и прогноз фобических расстройств. Журн. невропатол. и психиатр. 1998;(10):8-11.</p><p>Мосолов С.Н. Обсессивно-компульсивное расстройство. М., 2005;36 с.</p><p>Павличенко А.В. Множественные тревожно-фобические и обсессивно-компульсивные расстройства при шизофрении (феноменология, динамика, коморбидность). Автореф. дис. ... канд. мед. наук. М., 2007.</p><p>Калинин В.В., Сулимов Г.Ю. Купирование острой психотической симптоматики у больных шизофренией атипичным нейролептиком рисполепт: сравнение с классическими нейролептиками. Психиатр. и психофармакотер. 2000;(3):69-71.</p></div><br />
Review
For citations:
Pavlichenko A.V., Kessel'man L.G. PSYCHOPHARMOCOTHERAPY FOR PHOBIC AND OBSESSIVE-COMPULSIVE DISORDERS IN SCHIZOPHRENIA SPECTRUM STATES. Neurology, Neuropsychiatry, Psychosomatics. 2009;1(3-4):53-57. (In Russ.) https://doi.org/10.14412/2074-2711-2009-56
Views: 687
Email this article 